Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01168232 · OUTCOME

Objective Tumor Response

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage
Interval / dispersion
95% Confidence Interval
Time frame
Every other cycle for first 6 months; then every 3 months thereafter until completion of study treatment; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.1 cycle is 21 days

What was measured

Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response as assessed by RECIST 1.1.

Analysis population: Eligible and Treated Patients. Measure of dispersion is 95% One-sided confidence Interval

Groups in this outcome

Ixabepilone

Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ixabepilone34

Reported measurements

Source class 1
Values in percentage · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Ixabepilone11.8Not reported4.2100Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.2
        upper Limit
        100
        value
        11.8
denoms
  1. counts
    1. group Id
      OG000
      value
      34
    units
    Participants
description
Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response as assessed by RECIST 1.1.
dispersion Type
95% Confidence Interval
groups
  1. description
    Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment
    id
    OG000
    title
    Ixabepilone
param Type
NUMBER
population Description
Eligible and Treated Patients. Measure of dispersion is 95% One-sided confidence Interval
reporting Status
POSTED
time Frame
Every other cycle for first 6 months; then every 3 months thereafter until completion of study treatment; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.1 cycle is 21 days
title
Objective Tumor Response
type
PRIMARY
unit Of Measure
percentage

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice